Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by JDavenporton Sep 15, 2021 12:50pm
419 Views
Post# 33862372

Worth...

Worth...
I never know  whether I should respond to a post like cmonreally24's, or what to say if I do respond.
 
He's right. I'm not wealthy. I have been quite wealthy, a couple of times, briefly, but I was never any good at wealth. Whenever I had money, I didn't spent it on anything. I just let it ride while I pursued the things that interested me - science, literature, politics, family, cooking, social issues, music, esoterica. The satisfaction of curiosity.  It's probably an affliction, attention deficit disorder, maybe, or maybe something on the autism spectrum, or both, or neither. In the end, I'm like Popeye, "I yam what I yam."
 
Bioasis and xB3 have held my interest for 10 years. The xB3 Platform is very difficult to accurately assess as an investment opportunity. The science of receptor mediated transcytosis remains not as well understood as we would hope. The many diseases that might be treated with drugs transported by xB3 are all very complex. As investors we try to grasp some understanding of each of the diseases, but it's a hopeless quest. Large teams of scientific and medical researchers spend their lives working on only one or two diseases. How can we learn enough about all of the neurodisorders to have much of an idea about what's going on? In the end, we rely on researchers finding the drugs that work, and Bioasis being able to get them into the brain. We know that success with that should be very valuable.
 
What I am or am not is of little consequence. You can measure my worth with money if you wish. I do that sometimes, and it embarrasses me, both the act of assessment and its results. But then I'll grab my Canon EOS 7D Mark II, that I have studied to the point of technical fluency, and I grab two or three lenses and walk down to West Fraser Park, here in the beautiful and affluent City of Quesnel, 10 minutes from my poor home, and photograph the maple trees in their green to red passage of autumn glory.  I'll sit on a bench on the lake and watch the ducks and geese glide by. 
 
And then I'll go back to my desk and read about the relative distributions of Tf and LRP1 receptors in the BBB and brain parenchyma of mice, and then of humans, and then try to contemplate what the mathematics of those relative distributions might mean in a more meaningful comparison of xB3 to Denali's TV technology. And whether the distribution of LRP1 might affect how pharmaceutical companies consider deal-making with Bioasis. And whether that distribution explains why deals were never done until Bioasis completed at least some preclinical work and began to answer the questions. And whether the answers will be sufficient for getting the larger deals done, deals we have always expected and cannot fully understand why they haven't happened yet.
 
And then I'll watch the ball game, which will be interrupted occasionally by the wonder of the awfulness of people like cmonreally24, who think that planting that awfulness onto another human somehow could be satisfying for them, devastating to the object, and edifying to others.
 
I've probably paid too much for this life I have, but the ad hoc nurturing of one's soul is worth the exploration and its cost, especially when it all turns serendipitous, which it often does.
 
I have asked Stockhouse to delete cmonreally24's post, and my immediate response to it.
 
Yes, now, back to work, and worth. 
 
jd
 

<< Previous
Bullboard Posts
Next >>